deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT02750254

Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

Sponsor: Washington University School of Medicine

Conditions Acute Lymphocytic Leukemia Acute Myeloid Leukemia Myelodysplastic Syndrome
Interventions Azacitidine Busulfan Cyclophosphamide Fludarabine Fractionated total body irradiation Granulocyte-colony stimulating factor Melphalan Single dose total body irradiation Stem cell transplant
Updated 12 times since 2017 Last updated: Oct 16, 2020 Started: Jun 27, 2016 Primary completion: May 24, 2017 Completion: Oct 14, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Toxicity. Only enrolled patients in phase I portion of trial.

Other terminated trials from Washington University School of Medicine

See all terminations from Washington University School of Medicine

Other Acute Lymphocytic Leukemia trials with similar outcome

Browse all Acute Lymphocytic Leukemia trials

A PHASE1 clinical study on Acute Lymphocytic Leukemia and Acute Myeloid Leukemia, this trial is terminated or withdrawn. The trial is conducted by Washington University School of Medicine and has accumulated 12 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshotRecruiting~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshotActive Not Recruiting~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshotActive Not Recruiting~Apr 2019 – ~Jun 2020 · 14 months · monthly snapshotActive Not Recruiting~Jun 2020 – ~Nov 2020 · 5 months · monthly snapshotActive Not Recruiting~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 12 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  5. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

▶ Show 7 earlier versions

  1. Jun 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1

  2. Apr 2019 — Jun 2020 [monthly]

    Active Not Recruiting PHASE1

  3. Jun 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1

  4. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Phase: PHASE1_PHASE2 → PHASE1

  5. Oct 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Washington University School of Medicine
Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations